BERNSTEIN, BARRY M.,MENON, RAJEEV M.,KHATRI, AMIT,MENSING, SVEN,DUTTA, SANDEEP,COHEN, DANIEL E.,PODSADECKI, THOMAS J.,BRUN, SCOTT C.,AWNI, WALID M.,DUMAS, EMILY O.,KLEIN, CHERI E.
申请号：
CL2014000777
公开号：
CL2014000777A1
申请日:
2014.03.28
申请国别(地区):
CL
年份:
2014
代理人:
摘要：
The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.USO DE UNA COMBINACIÓN DE AL MENOS DOS AGENTES ANTIVIRALES DE ACCIÓN DIRECTA (DAAs) Y RIBAVIRINA Y QUE NO INCLUYE INTERFERÓN, PARA EL TRATAMIENTO DEL VIRUS DE HEPATITIS C (HCV).
